218 related articles for article (PubMed ID: 35832075)
1. Blockade of phosphotyrosine pathways suggesting SH2 superbinder as a novel therapy for pulmonary fibrosis.
Wang M; Liu AD; Niu Q; Feng X; Zheng YY; Chen SJ; Xu H; Li Q; Hou GQ; Bi XY; Lu YZ; Cheng PP; Liang LM; Jiang YH; Zhao LQ; Liu F; Song LJ; Zhou LL; Xiao LY; Chen F; Li SS; Ma WL; Cao X; Ye H
Theranostics; 2022; 12(10):4513-4535. PubMed ID: 35832075
[No Abstract] [Full Text] [Related]
2. (Arg)
Liu AD; Xu H; Gao YN; Luo DN; Li ZF; Voss C; Li SSC; Cao X
J Exp Clin Cancer Res; 2018 Jul; 37(1):138. PubMed ID: 29976230
[TBL] [Abstract][Full Text] [Related]
3. Protein-phosphotyrosine proteome profiling by superbinder-SH2 domain affinity purification mass spectrometry, sSH2-AP-MS.
Tong J; Cao B; Martyn GD; Krieger JR; Taylor P; Yates B; Sidhu SS; Li SS; Mao X; Moran MF
Proteomics; 2017 Mar; 17(6):. PubMed ID: 27880036
[TBL] [Abstract][Full Text] [Related]
4. Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma.
Liu AD; Zhou J; Bi XY; Hou GQ; Li SS; Chen Q; Xu H; Cao X
Clin Transl Med; 2021 Mar; 11(3):e337. PubMed ID: 33783993
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis.
Epstein Shochet G; Bardenstein-Wald B; McElroy M; Kukuy A; Surber M; Edelstein E; Pertzov B; Kramer MR; Shitrit D
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805152
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
[TBL] [Abstract][Full Text] [Related]
7. Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis.
Ahangari F; Becker C; Foster DG; Chioccioli M; Nelson M; Beke K; Wang X; Justet A; Adams T; Readhead B; Meador C; Correll K; Lili LN; Roybal HM; Rose KA; Ding S; Barnthaler T; Briones N; DeIuliis G; Schupp JC; Li Q; Omote N; Aschner Y; Sharma L; Kopf KW; Magnusson B; Hicks R; Backmark A; Dela Cruz CS; Rosas I; Cousens LP; Dudley JT; Kaminski N; Downey GP
Am J Respir Crit Care Med; 2022 Dec; 206(12):1463-1479. PubMed ID: 35998281
[No Abstract] [Full Text] [Related]
8. Bleomycin Induces Drug Efflux in Lungs. A Pitfall for Pharmacological Studies of Pulmonary Fibrosis.
Park JK; Coffey NJ; Bodine SP; Zawatsky CN; Jay L; Gahl WA; Kunos G; Gochuico BR; Malicdan MCV; Cinar R
Am J Respir Cell Mol Biol; 2020 Feb; 62(2):178-190. PubMed ID: 31419911
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
Epstein Shochet G; Wollin L; Shitrit D
Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
[TBL] [Abstract][Full Text] [Related]
10. The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.
Araki K; Kinoshita R; Tomonobu N; Gohara Y; Tomida S; Takahashi Y; Senoo S; Taniguchi A; Itano J; Yamamoto KI; Murata H; Suzawa K; Shien K; Yamamoto H; Okazaki M; Sugimoto S; Ichimura K; Nishibori M; Miyahara N; Toyooka S; Sakaguchi M
J Mol Med (Berl); 2021 Jan; 99(1):131-145. PubMed ID: 33169236
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
12. Invadosome Formation by Lung Fibroblasts in Idiopathic Pulmonary Fibrosis.
Lebel M; Cliche DO; Charbonneau M; Adam D; Brochiero E; Dubois CM; Cantin AM
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613948
[TBL] [Abstract][Full Text] [Related]
13. SH2 Domain-Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis.
Tzouvelekis A; Yu G; Lino Cardenas CL; Herazo-Maya JD; Wang R; Woolard T; Zhang Y; Sakamoto K; Lee H; Yi JS; DeIuliis G; Xylourgidis N; Ahangari F; Lee PJ; Aidinis V; Herzog EL; Homer R; Bennett AM; Kaminski N
Am J Respir Crit Care Med; 2017 Feb; 195(4):500-514. PubMed ID: 27736153
[TBL] [Abstract][Full Text] [Related]
14. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
15. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
Espindola MS; Habiel DM; Narayanan R; Jones I; Coelho AL; Murray LA; Jiang D; Noble PW; Hogaboam CM
Am J Respir Crit Care Med; 2018 Jun; 197(11):1443-1456. PubMed ID: 29634284
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting Fibroblast Mechanotransduction Modulates Severity of Idiopathic Pulmonary Fibrosis.
Trotsyuk AA; Chen K; Hyung S; Ma KC; Henn D; Mermin-Bunnell AM; Mittal S; Padmanabhan J; Larson MR; Steele SR; Sivaraj D; Bonham CA; Noishiki C; Rodrigues M; Jiang Y; Jing S; Niu S; Chattopadhyay A; Perrault DP; Leeolou MC; Fischer KS; Gurusankar G; Choi Kussie H; Wan DC; Januszyk M; Longaker MT; Gurtner GC
Adv Wound Care (New Rochelle); 2022 Oct; 11(10):511-523. PubMed ID: 34544267
[No Abstract] [Full Text] [Related]
17. Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis.
Xie Y; Jiang H; Zhang Q; Mehrotra S; Abel PW; Toews ML; Wolff DW; Rennard S; Panettieri RA; Casale TB; Tu Y
Respir Res; 2016 Aug; 17(1):103. PubMed ID: 27549302
[TBL] [Abstract][Full Text] [Related]
18. Andrographolide ameliorates bleomycin-induced pulmonary fibrosis by suppressing cell proliferation and myofibroblast differentiation of fibroblasts via the TGF-β1-mediated Smad-dependent and -independent pathways.
Li J; Feng M; Sun R; Li Z; Hu L; Peng G; Xu X; Wang W; Cui F; Yue W; He J; Liu J
Toxicol Lett; 2020 Mar; 321():103-113. PubMed ID: 31706003
[TBL] [Abstract][Full Text] [Related]
19. Tackling MARCKS-PIP3 circuit attenuates fibroblast activation and fibrosis progression.
Yang DC; Li JM; Xu J; Oldham J; Phan SH; Last JA; Wu R; Chen CH
FASEB J; 2019 Dec; 33(12):14354-14369. PubMed ID: 31661644
[TBL] [Abstract][Full Text] [Related]
20. Reversion of in vivo fibrogenesis by novel chromone scaffolds.
Kim HS; Yoon YM; Meang MK; Park YE; Lee JY; Lee TH; Lee JE; Kim IH; Youn BS
EBioMedicine; 2019 Jan; 39():484-496. PubMed ID: 30611717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
